JP2022512538A5 - - Google Patents
Info
- Publication number
- JP2022512538A5 JP2022512538A5 JP2021510452A JP2021510452A JP2022512538A5 JP 2022512538 A5 JP2022512538 A5 JP 2022512538A5 JP 2021510452 A JP2021510452 A JP 2021510452A JP 2021510452 A JP2021510452 A JP 2021510452A JP 2022512538 A5 JP2022512538 A5 JP 2022512538A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- population
- seq
- acid sequence
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862771653P | 2018-11-27 | 2018-11-27 | |
| US62/771,653 | 2018-11-27 | ||
| PCT/US2019/063310 WO2020112815A1 (en) | 2018-11-27 | 2019-11-26 | Anti-lmp2 tcr-t cell therapy for the treatment of ebv-associated cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022512538A JP2022512538A (ja) | 2022-02-07 |
| JP2022512538A5 true JP2022512538A5 (https=) | 2022-12-05 |
Family
ID=70854398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510452A Pending JP2022512538A (ja) | 2018-11-27 | 2019-11-26 | Ｅｂｖ関連がんの処置のための抗ｌｍｐ２ ｔｃｒ－ｔ細胞療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12139523B2 (https=) |
| JP (1) | JP2022512538A (https=) |
| KR (1) | KR20210098940A (https=) |
| CN (1) | CN113166224A (https=) |
| SG (1) | SG11202101671PA (https=) |
| TW (1) | TW202039540A (https=) |
| WO (1) | WO2020112815A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113621070A (zh) | 2020-05-06 | 2021-11-09 | 华夏英泰（北京）生物技术有限公司 | 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用 |
| WO2021243695A1 (en) * | 2020-06-05 | 2021-12-09 | Guangdong Tcrcure Biopharma Technology Co., Ltd. | Tcr-t cell therapy targeting epstein-barr virus |
| CN112940108B (zh) * | 2021-03-19 | 2022-10-14 | 河南省肿瘤医院 | 识别ebv抗原的t细胞受体以及该t细胞受体的应用 |
| WO2023092452A1 (zh) * | 2021-11-26 | 2023-06-01 | 上海吉倍生物技术有限公司 | 识别ebv lmp2抗原的t细胞受体及其应用 |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| CN119390814B (zh) * | 2023-10-26 | 2025-06-27 | 上海市第一人民医院 | 一种t细胞受体及其制备方法和用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0917090D0 (en) * | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| US8834889B2 (en) * | 2011-08-29 | 2014-09-16 | National Tsing Hua University | Antigen presenting composition and use thereof |
| GB201314404D0 (en) | 2013-08-12 | 2013-09-25 | Immunocore Ltd | T Cell Receptors |
| WO2016095783A1 (zh) | 2014-12-17 | 2016-06-23 | 中国科学院广州生物医药与健康研究院 | 识别eb病毒短肽的t细胞受体 |
| US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
| GB201520191D0 (en) * | 2015-11-16 | 2015-12-30 | Cancer Rec Tech Ltd | T-cell receptor and uses thereof |
| GB201522592D0 (en) | 2015-12-22 | 2016-02-03 | Immunocore Ltd | T cell receptors |
| CN106632659A (zh) * | 2016-08-05 | 2017-05-10 | 武汉赛云博生物科技有限公司 | 一种eb病毒特异性tcr及其重组慢病毒载体与应用 |
| MX2019003768A (es) * | 2016-10-03 | 2019-06-24 | Juno Therapeutics Inc | Moleculas de enlace especificas de hpv. |
| CN110582509A (zh) | 2017-01-31 | 2019-12-17 | 诺华股份有限公司 | 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症 |
-
2019
- 2019-11-26 US US17/276,553 patent/US12139523B2/en active Active
- 2019-11-26 JP JP2021510452A patent/JP2022512538A/ja active Pending
- 2019-11-26 KR KR1020217005780A patent/KR20210098940A/ko not_active Ceased
- 2019-11-26 CN CN201980056915.5A patent/CN113166224A/zh active Pending
- 2019-11-26 SG SG11202101671PA patent/SG11202101671PA/en unknown
- 2019-11-26 WO PCT/US2019/063310 patent/WO2020112815A1/en not_active Ceased
- 2019-11-27 TW TW108143260A patent/TW202039540A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022512538A5 (https=) | ||
| Verbeke et al. | Broadening the message: a nanovaccine co-loaded with messenger RNA and α-GalCer induces antitumor immunity through conventional and natural killer T cells | |
| ES3061201T3 (en) | Methods and compositions for modified t cells | |
| JP7546925B2 (ja) | 核酸とｃａｒ修飾免疫細胞とを含む治療薬およびその使用 | |
| TWI710572B (zh) | 改善配對的ｔ細胞受體 | |
| ES2777305T5 (en) | Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy | |
| Rommelfanger et al. | Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer | |
| US9238064B2 (en) | Allogeneic cancer cell-based immunotherapy | |
| ES2910227T3 (es) | Composición y métodos para la estimulación y expansión de células T | |
| JP2017533706A5 (https=) | ||
| CN111051502A (zh) | 通用型嵌合抗原受体t细胞制备技术 | |
| AU2017235116A1 (en) | Immunocompetent cell and expression vector expressing regulatory factors of immune function | |
| CN105802909B (zh) | 具有her2特异性tcr的t细胞制备物及其用途 | |
| CN113330038A (zh) | Cd20组合靶向的工程化免疫细胞 | |
| JP2022519704A5 (https=) | ||
| CN110564767A (zh) | 一种减毒病毒载体系统及其在制备抗恶性肿瘤的药物中的应用及药物使用方法 | |
| JPH10511542A (ja) | 標的化ｔリンパ球 | |
| CN109554349B (zh) | Pd-1基因表达沉默的工程化免疫细胞 | |
| Hanagiri et al. | Retracted: Antitumor activity of human γδ T cells transducted with CD 8 and with T‐cell receptors of tumor‐specific cytotoxic T lymphocytes | |
| US20210332381A1 (en) | Ligand Matched Transcription Control, Control Devices, and Solute Carriers | |
| Park et al. | Efficient induction of anti-tumor immunity by a TAT-CEA fusion protein vaccine with poly (I: C) in a murine colorectal tumor model | |
| Larsen et al. | Lymphoproliferative disorders: prospects for gene therapy | |
| Kim | Development of Genetically Modified Tumor Cell Containing Co-stimulatory Molecule | |
| Bella-Carreño et al. | Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis | |
| WO2024179518A1 (zh) | 具有优化的itam结构域及cd28与4-1bb双共刺激分子的双靶点car-t |